Please contact us for more information or to learn if you are eligible to participate.
To evaluate the safety and tolerability of once-daily, oral administration of resmetirom for 52 weeks.
Principal Investigator | Fernando Membreno, MD |
Co-PI | John Rodriguez |
Sponsor | Madrigal Pharmaceuticals, Inc. |
Type of Trial | Interventional |